BST

Funding Circle Plc:

Retrieved on: 
Tuesday, August 22, 2023
Webcast, Small business, Uncial 0200, BST

Funding Circle, the lending platform for small business borrowers, will announce its results for the half year ended 30 June 2023 on Thursday, 7 September 2023 at 7:00am UK time (BST).

Key Points: 
  • Funding Circle, the lending platform for small business borrowers, will announce its results for the half year ended 30 June 2023 on Thursday, 7 September 2023 at 7:00am UK time (BST).
  • To watch and listen to the webcast, with the opportunity to submit written questions, please use this link to register and gain access to the event.
  • For conference call access, with the opportunity to ask live questions, please dial either +44 33 0551 0200 (UK) or +1 786 697 3501 (US).
  • Quote Funding Circle Half Year when prompted by the operator.

Nagarro posts 16.5% YoY revenue growth in constant currency in H1 2023 despite global macroeconomic challenges

Retrieved on: 
Monday, August 14, 2023
CT, GST, IST, Face, PT, EBIT, Organic, ET, EBITDA, Acquisition, Investment, CEST, Yoy, Growth, BST, Beauty salon

MUNICH, Aug. 14, 2023 /PRNewswire/ -- Nagarro's superior client experience and its strategic diversification continued to deliver resilient growth in the face of global economic uncertainties. In Q2 2023, revenue grew to €226.8 million, up 8.0% YoY from €210.0 million in Q2 2022. Constant currency YoY revenue growth for Q2 2023 was 10.7%. Organic YoY revenue growth for the quarter was 8.7% in constant currency, which translated to 6.1% organic YoY revenue growth in Euro terms. Gross profit declined to €57.5 million in Q2 2023 from €60.2 million in Q2 2022. Due to excess production capacity which is reflected in the cost of revenues, gross margin dropped to 25.3% in Q2 2023 from 28.7% in Q2 2022. Adjusted EBITDA declined to €28.9 million (12.8% of revenue) in Q2 2023, from €40.2 million (19.1% of revenue) in Q2 2022.

Key Points: 
  • In Q2 2023, revenue grew to €226.8 million, up 8.0% YoY from €210.0 million in Q2 2022.
  • Organic YoY revenue growth for the quarter was 8.7% in constant currency, which translated to 6.1% organic YoY revenue growth in Euro terms.
  • Organic YoY revenue growth for H1 2023 was 14.9% in constant currency, which translated to 14.2% organic YoY revenue growth in Euro terms.
  • Adjusted EBITDA declined to €60.3 million (13.2 % of revenue) in H1 2023, from €69.1 million (17.5% of revenue) in H1 2022.

Nagarro posts 16.5% YoY revenue growth in constant currency in H1 2023 despite global macroeconomic challenges

Retrieved on: 
Monday, August 14, 2023
CT, GST, IST, Face, PT, EBIT, Organic, ET, EBITDA, Acquisition, Investment, CEST, Yoy, Growth, BST, Beauty salon

MUNICH, Aug. 14, 2023 /PRNewswire/ -- Nagarro's superior client experience and its strategic diversification continued to deliver resilient growth in the face of global economic uncertainties. In Q2 2023, revenue grew to €226.8 million, up 8.0% YoY from €210.0 million in Q2 2022. Constant currency YoY revenue growth for Q2 2023 was 10.7%. Organic YoY revenue growth for the quarter was 8.7% in constant currency, which translated to 6.1% organic YoY revenue growth in Euro terms. Gross profit declined to €57.5 million in Q2 2023 from €60.2 million in Q2 2022. Due to excess production capacity which is reflected in the cost of revenues, gross margin dropped to 25.3% in Q2 2023 from 28.7% in Q2 2022. Adjusted EBITDA declined to €28.9 million (12.8% of revenue) in Q2 2023, from €40.2 million (19.1% of revenue) in Q2 2022.

Key Points: 
  • In Q2 2023, revenue grew to €226.8 million, up 8.0% YoY from €210.0 million in Q2 2022.
  • Organic YoY revenue growth for the quarter was 8.7% in constant currency, which translated to 6.1% organic YoY revenue growth in Euro terms.
  • Organic YoY revenue growth for H1 2023 was 14.9% in constant currency, which translated to 14.2% organic YoY revenue growth in Euro terms.
  • Adjusted EBITDA declined to €60.3 million (13.2 % of revenue) in H1 2023, from €69.1 million (17.5% of revenue) in H1 2022.

Exscientia Business Update for Second Quarter and First Half of 2023

Retrieved on: 
Thursday, August 10, 2023
Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Pancreatic cancer, Federal Reserve Bank, LSD1, International, Sumitomo Pharma, IGNITE, Pharmacokinetics, CDK7, Head, G&A, PKC, NSCLC, Bristol Myers Squibb, Lung cancer, Harvard University, ID, EDT, USD, MALT1, Publication, Patient, Machine learning, Medicine, Growth, AI, Ovarian cancer, GBP, Safety, Automation, BST, Communications satellite, Pharmaceutical industry, Management, Cryptocurrency, Rare-earth element, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below.
  • “In the first half of 2023, four molecules precision-designed by Exscientia advanced further into clinical trials, a significant achievement as we progress our growing pipeline,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.
  • Research and development expenses in the second quarter 2023 were relatively flat over the second quarter 2022, as areas of pipeline and operational growth were offset by efficiency and cost savings activities.
  • Cash inflows: For the second quarter 2023, Exscientia received $0.7 million in cash inflows from its collaborations as compared to $111.0 million during the second quarter 2022, when the upfront payment for the Sanofi collaboration was received.

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Research fellow, Insurance, Net, G&A, CHF, Research, Participation, D&O, Q&A, Biology, EDT, BST, Renewable energy, Indivior

During the first half of 2023, income increased by CHF 0.7 million to CHF 1.1 million compared to CHF 0.4 million in the first half of 2022.

Key Points: 
  • During the first half of 2023, income increased by CHF 0.7 million to CHF 1.1 million compared to CHF 0.4 million in the first half of 2022.
  • During the second quarter of 2023, income increased by CHF 0.4 million to CHF 0.6 million compared to CHF 0.2 million in the second quarter of 2022.
  • R&D expenses decreased by CHF 5.9 million to CHF 3.6 million in the first half of 2023 compared to CHF 9.5 million in the first half of 2022 and by CHF 3.9 million to CHF 1.8 million in the second quarter of 2023 compared to CHF 5.7 million in the second quarter of 2022.
  • Our net loss decreased by CHF 8.0 million to CHF 5.0 million in the first half of 2023 compared to CHF 13.0 million in the first half of 2022 and by CHF 4.5 million to CHF 2.7 million in the second quarter of 2023 compared to CHF 7.2 million in the second quarter of 2022.

Notice of 2023 Half Year Results and Investor Presentations

Retrieved on: 
Tuesday, August 8, 2023
Kurdistan Region, Gulf Keystone Petroleum, BST, IMC

Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq, confirms it will be announcing its results for the half year ended 30 June 2023 on Thursday 31 August 2023.

Key Points: 
  • Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq, confirms it will be announcing its results for the half year ended 30 June 2023 on Thursday 31 August 2023.
  • GKP’s management team will be hosting a presentation for analysts and investors at 10:00am (BST) via live audio webcast:
    The presentation is open to all existing and potential shareholders.
  • Questions can be submitted prior to the event via the IMC platform up until 9:00am (BST) the day before the meeting, or at any time during the live presentation.
  • Investors can sign up to IMC for free using the following link:
    Recordings of both presentations will be made available on GKP’s website.

Faron Pharmaceuticals Notice of Half-Year Financial Results

Retrieved on: 
Friday, August 4, 2023
Nasdaq First North, Faron Pharmaceuticals, AIM, Q&A, EEST, EDT, Cancer, BST

TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.

Key Points: 
  • TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.
  • A live virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and James O’Brien, Chief Financial Officer, at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on the day of results.
  • For more information please contact:

MBH Corporation Plc: Share Consolidation Update

Retrieved on: 
Friday, August 4, 2023
Treasury, SEDOL, IR, Frankfurt Stock Exchange, MBH, AGM, United Nations Security Council Resolution 13, Application, CEST, Consolidation, Admission, ISIN, FCA, Disclosure, BST, Security (finance)

MBH Corporation plc (MBH), a diversified investment holding company, announces that following shareholders’ approval of Resolution 13 (as detailed in the Notice of the AGM Circular dated 26 May 2023) at the AGM held on 28 June 2023, every 30 ordinary shares of  €0.01 each (the “Existing Ordinary Shares”) will be consolidated into 1 new ordinary share of  €0.30 each (the “New Ordinary Shares” and the “Consolidation”).

Key Points: 
  • MBH Corporation plc (MBH), a diversified investment holding company, announces that following shareholders’ approval of Resolution 13 (as detailed in the Notice of the AGM Circular dated 26 May 2023) at the AGM held on 28 June 2023, every 30 ordinary shares of  €0.01 each (the “Existing Ordinary Shares”) will be consolidated into 1 new ordinary share of  €0.30 each (the “New Ordinary Shares” and the “Consolidation”).
  • Other than the change in nominal value, the New Ordinary Shares arising on implementation of the Consolidation will have the same rights as the Existing Ordinary Shares, including voting and dividend rights.
  • The number of total voting rights in the Company's issued ordinary share capital will decrease as a result of the Consolidation.
  • Accordingly, following Admission, the Company's enlarged issued voting share capital will comprise 4,135,428 New Ordinary Shares.

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Retrieved on: 
Friday, August 4, 2023
Research fellow, Webcast, Biology, Discovery, Therapy, SIX, Participation, BST, EDT, Pharmaceutical industry

Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023.

Key Points: 
  • Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023.
  • Participants are required to register in advance of the conference using the link provided below.
  • Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
  • In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering.

EQS-News: Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Retrieved on: 
Thursday, August 3, 2023
Webcast, Management, MorphoSys, FSE, Q&A, Conference, CEST, EDT, BST, Clothing, Video game

Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023

Key Points: 
  • Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on August 10, 2023, at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the second quarter and first half 2023 and provide an outlook for 2023.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.